Therefore, the elevated expression of PTGS2 in circulating monocyte subtypes plays a pivotal role in gout flares and could underpin the molecular basis for the use of COX2 selective inhibitors as a first-line treatment for gout flares. Here, PTGER2 is linked to gout.